Relationship between NAT1 genotype and phenotype in a Japanese population

Pharmacogenetics

Volumn 10, Issue 3, 2000, Pages 225-232

  Yang, Mihi ^a,b,e   Katoh, Takahiko ^c   Delongchamp, Robert ^a   Ozawa, Shogo ^d   Kohshi, Kiyotaka ^b   Kawamoto, Toshihiro ^b  

^a National Center for Toxicological Research   (United States)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^e National Center for Toxicology Research   (United States)

Author keywords

Genotype; Japanese; NAT1; Phenotype

Indexed keywords

ACYLTRANSFERASE;

ADULT; AGE; AGED; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; JAPAN; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOKING; STATISTICAL ANALYSIS;

NICOTIANA TABACUM;

EID: 0034050139     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200004000-00003     Document Type: Article

References (21)

1. Agreti A, Coull BA. Approximate is better than exact for interval estimation of binomial proportions. Am Statistic 1998; 52:119-126.
2. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995; 55:5230-5237.
3. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995a; 55:3537-3542.
4. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995b; 55:5226-5229.
5. Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560 A mutations. Pharmacogenetics 1998; 8:67-72.
6. Cribb AE, Grant DM, Miller MA, Spielberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Ther 1991; 259:1241-1246.
7. Frame LT, Ambrosone CB, Kadlubar FF, Lang NP. Host-environment interactions that affect variability in human cancer susceptibility. In: Neumann DA, Kimmel CA, editors. Human variability in response to chemical exposure. Washington DC: ILSI Press; 1998, pp. 165-204.
8. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376:61-70.
9. Hughes NC, Janezic SA, McQueen KL, Jewett MA, Castranio T, Bell DA, Grant DM. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998; 8:55-66.
10. Juberg DR, Bond JT, Weber WW. N-acetylation of aromatic amines: genetic polymorphism in inbred rat strains. Pharmacogenetics 1991; 1:50-57.
11. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 1998; 19:1803-1807.
12. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, Kau IH, et al. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 1998; 8:269-281.
13. Lowry OH, Rosebrough AE, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275.
14. Meisler MH, Reinke C. A sensitive fluorescent assay for N-acetyltransferase activity in human lymphocytes from newborns and adults. Clin Chim Acta 1979; 96:91-96.
15. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, Kadlubar FF. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 1992; 185:839-44.
16. Probst-Hensch NM, Haile RW, Li DS, Sakamoto GT, Louie AD, Lin BK, et al. Lack of association between the polyadenylation polymorphism in the NAT1 (acelyltransferase 1) gene and colorectal adenomas. Carcinogenesis 1996; 17:2125-2129.
17. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 1998; 58:3603-3610.
18. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5:1-17.
19. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics 1993; 3:209-212.
20. Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999; 29:59-124.
21. Zhao B, Lee EJ, Yeoh PN, Gong NH. Detection of mutations and polymorphism of N-acetyltransferase 1 gene in Indian, Malay and Chinese populations. Pharmacogenetics 1998; 8:299-304.